Charles River Laboratories International, Inc.
$184.36
▲
0.69%
2026-04-22 10:12:13
www.criver.com
NYQ: CRL
Explore Charles River Laboratories International, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.17 B
Current Price
$184.36
52W High / Low
$228.88 / $99.8
Stock P/E
—
Book Value
$64.3
Dividend Yield
—
ROCE
6.67%
ROE
-4.23%
Face Value
—
EPS
$-2.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
18,300
Beta
1.62
Debt / Equity
81.95
Current Ratio
1.29
Quick Ratio
1.02
Forward P/E
14.14
Price / Sales
2.16
Enterprise Value
$11.11 B
EV / EBITDA
12.68
EV / Revenue
2.77
Rating
Buy
Target Price
$197.64
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Sotera Health Company | $16.28 | 59.4 | $4.63 B | — | 12.01% | 15.42% | $19.85 / $10.17 | $2.13 |
| 2. | Check-Cap Ltd. | $1.9 | — | $13.56 M | — | 659.83% | -1.3% | $3.92 / $0.59 | $0.64 |
| 3. | Waters Corporation | $332.95 | 30.93 | $32.76 B | — | 20.92% | 29.28% | $414.15 / $275.05 | $43.01 |
| 4. | Labcorp Holdings Inc. | $271.17 | 25.93 | $22.36 B | 1.07% | 9.74% | 10.51% | $293.72 / $209.38 | $104.86 |
| 5. | RadNet, Inc. | $57.85 | — | $4.48 B | — | 2.63% | 1.37% | $85.84 / $46.76 | $14.08 |
| 6. | Guardant Health, Inc. | $90.8 | — | $11.97 B | — | -25.56% | 348.42% | $120.74 / $36.36 | $-0.76 |
| 7. | GRAIL, Inc. | $51.2 | — | $2.1 B | — | -18.79% | -16.07% | $118.84 / $25.56 | $63.92 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 994.23 M | 1 B | 1.03 B | 984.17 M | 1 B | — |
| Operating Profit | 92.53 M | 133.8 M | 100.13 M | 74.67 M | 47.31 M | — |
| Net Profit | -276.56 M | 54.42 M | 52.33 M | 25.47 M | -215.7 M | — |
| EPS in Rs | -5.6 | 1.1 | 1.06 | 0.52 | -4.37 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.02 B | 4.05 B | 4.13 B | 3.98 B |
| Operating Profit | 401.14 M | 442.35 M | 617.26 M | 650.98 M |
| Net Profit | -144.34 M | 10.3 M | 474.62 M | 486.23 M |
| EPS in Rs | -2.93 | 0.21 | 9.62 | 9.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.14 B | 7.53 B | 8.2 B | 7.6 B |
| Total Liabilities | 3.92 B | 4.02 B | 4.54 B | 4.58 B |
| Equity | 3.16 B | 3.46 B | 3.6 B | 2.98 B |
| Current Assets | 1.45 B | 1.4 B | 1.61 B | 1.44 B |
| Current Liabilities | 1.12 B | 994.1 M | 1.06 B | 1.09 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 737.65 M | 734.58 M | 683.9 M | 619.64 M |
| Investing CF | -209.32 M | -245.09 M | -563.15 M | -607.92 M |
| Financing CF | -536.73 M | -550.93 M | -85.52 M | -42.4 M |
| Free CF | 518.49 M | 501.61 M | 365.37 M | 294.91 M |
| Capex | -219.15 M | -232.97 M | -318.53 M | -324.73 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -0.85% | -1.92% | 3.86% | — |
| Earnings Growth % | -1501.75% | -97.83% | -2.39% | — |
| Profit Margin % | -3.59% | 0.25% | 11.49% | 12.23% |
| Operating Margin % | 9.99% | 10.92% | 14.95% | 16.37% |
| Gross Margin % | 32.96% | 32.88% | 36.39% | 36.79% |
| EBITDA Margin % | 10.23% | 14.35% | 24.99% | 24.8% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.